API & IP Brief: Dr. Reddy’s Patent Landscape, Semaglutide Revocation & Voquezna Updates
API & IP Intelligence Brief: Dr. Reddy’s Patent Strategy & Semaglutide Patent Revocation Keywords: Dr. Reddy's patent filings, Semaglutide patent revocation, EPO Board of Appeal T 0187/25, Factor XIa inhibitors, API solid-state forms, skinny label generic, Voquezna ANDA litigation . Dr. Reddy’s Patent Landscape: Early-Stage Generic Positioning An analysis of 24 patent applications published between October 2024 and October 2026 highlights Dr. Reddy’s Laboratories’ (DRL) aggressive pre-loss-of-exclusivity (LOE) strategy . Small-molecule generic enablement accounts for 67% (16 filings) of the total, divided between API process/solid-state chemistry (38%, 9 filings) and differentiated dosage forms (29%, 7 filings) . The remaining pipeline spans biologics (13%), nutraceuticals (8%), digital health (8%), and a single new chemical entity (NCE) pan-KRAS degrader filing from Aurigene Oncology (4%) . DRL is building alternative crystal forms, salts, amorphous solid dispersion...